Table 3

New agents in high-risk myeloma

AgentORRPFSOS
Carfilzomib46HR, 25.8%; SR, 24.6%HR, 3.5 mo; SR, 4.6 moHR, 9.3 mo; SR, 19 mo
Pomalidomide49del(17p), 32%; t(4;14), 22%HR, 7.3 mo; 2.8mHR, 12 mo; SR, 9 mo
Car/pom/dex51HR, 78%; SR, 74%HR, 9.7 mo; SR, NRHR, 16 mo; SR, 18 mo
  • Car/pom/dex, carfilzomib, pomalidomide, and dexamethasone; NR, not reported; ORR, overall response rate.